Rituximab, an anti-CD20-therapy that depletes B cells with high efficacy and tolerability, is used off-label for MS (in Sweden) . From studies in rheumatology  and in other autoimmune diseases, such as neuromyelitis optica spectrum disorders , hypogammaglobulinemia is a well-known side effect associated with rituximab which can lead to treatment discontinuation and susceptibility for infections.
Dr Susanna Hallberg (Karolinska Institute, Sweden) and colleagues investigated the risk of developing decreased levels of IgG and IgM during long-term treatment with rituximab in MS patients (n=1,933). They found that the risk of hypogammaglobulinemia is an important side-effect in long-term treatment with rituximab in MS, which is consistent with previous findings in other autoimmune diseases [2,3].
The main predictors for treatment-induced Ig decrease were total accumulated dose of rituximab, treatment duration, and initial level of IgG. IgG level...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Nivolumab + Ipilimumab Safe First-line Treatment for NSCLC Patients with Comorbidities Next Article
Longer OS with Atezolizumab + Carboplatin + Nab-paclitaxel in Advanced Squamous NSCLC »
Table of Contents: ECTRIMS 2019
Towards a Comprehensive Assessment of MS Course
Monitoring and Treatment of Progressive MS
Optimising Long-Term Benefit of MS Treatment
Safety Assessment in the Post-Approval Phase
Pregnancy in the Treatment Era
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.